Potent GCN2 Inhibitor Capable of Reversing MDSC-Driven T Cell Suppression Demonstrates In Vivo Efficacy as a Single Agent and in Combination with Anti-Angiogenesis Therapy
Jeffrey J. Jackson(Rapt Therapeutics (United States)), Mikhail Zibinsky(Rapt Therapeutics (United States)), Delia Bradford(Rapt Therapeutics (United States)), David J. Wustrow(Rapt Therapeutics (United States)), Jacob B. Schwarz(Rapt Therapeutics (United States)), Paul R. Leger(Rapt Therapeutics (United States)), Cyril Bucher(Rapt Therapeutics (United States)), Anton Shakhmin(Nanosyn (United States)), Maureen K. Reilly(Rapt Therapeutics (United States)), Daniel Poon(Rapt Therapeutics (United States)), Andrew A. Ng(Rapt Therapeutics (United States)), Xinping Han(Rapt Therapeutics (United States)), Buvana Ravishankar(Rapt Therapeutics (United States)), Grant M. Shibuya(Rapt Therapeutics (United States)), Gene Cutler(Rapt Therapeutics (United States)), Jack Maung(Rapt Therapeutics (United States)), Paul D. Kassner(Rapt Therapeutics (United States)), Anqi Ma(Rapt Therapeutics (United States)), Adrian Dukes(Rapt Therapeutics (United States)), Raashi Sreenivasan(Rapt Therapeutics (United States)), Scott Jacobson(Rapt Therapeutics (United States)), Hunter P. Shunatona(Rapt Therapeutics (United States)), Michelle Ko(Rapt Therapeutics (United States)), Lisa A. Marshall(Rapt Therapeutics (United States)), Mengshu Xu(University of Toronto), Omar Robles(Rapt Therapeutics (United States)), Deepa Pookot(Rapt Therapeutics (United States)), Thant Zaw(Rapt Therapeutics (United States)), Parcharee Tivitmahaisoon(Rapt Therapeutics (United States)), Cynthia Cho(Rapt Therapeutics (United States)), Dennis X. Hu(Rapt Therapeutics (United States)), Christoph Colas(Rapt Therapeutics (United States)), Lavanya Adusumilli(Rapt Therapeutics (United States)), Akinori Okano(Rapt Therapeutics (United States)), George E. Katibah(Rapt Therapeutics (United States)), Dirk G. Brockstedt(490 BioTech (United States)), Minna Bui(Rapt Therapeutics (United States)), Chandru Ramana(Rapt Therapeutics (United States)), Urvi Kolhatkar(Rapt Therapeutics (United States))
Cited by 12
Related Papers
Attitudes and perceptions of UK medical students towards artificial intelligence and radiology: a multicentre survey
|Insights into Imaging|2020|492
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
|Clinical Cancer Research|2019|260
Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
|Clinical Cancer Research|2020|151
Tumors establish resistance to immunotherapy by regulating T<sub>reg</sub>recruitment via CCR4
|Journal for ImmunoTherapy of Cancer|2020|141
Food, Shelter and Safety Needs Motivating Homeless Persons' Visits to an Urban Emergency Department
|Annals of Emergency Medicine|2008|100